Kornimate/medical-research-clean huggingface dataset:
pet study in parkinson's disease patients

Conditions: Parkinson's Disease

Summary: this is a multi-centre study to be conducted in sweden and finland. up to 24 male and/or female patients of non-childbearing potential aged 45 to 75 years (inclusive), with a clinical diagnosis parkinson's disease will be randomised in the study to allow for 20 patients to complete this study.the study will evaluate the effect of 8 weeks treatment with azd3241 on microglia activation as measured via pet examinations.

a phase iia, multi centre, double-blind, randomised, placebo-controlled, parallel-group study to assess the effect of 8 weeks treatment with oral azd3241 on microglia activation, as measured by positron emission tomography (pet), in patients with parkinson's disease

Eligibility criteria:
inclusion criteria: * female and male patients aged 45 to 75 years (inclusive) at the day of enrolment (visit 1) * female patients must have a negative pregnancy test at screening, must not be lactating and must be of non childbearing potential, confirmed at screening * male patients should be willing to use barrier contraception, eg, condoms, even if their partners are post-menopausal, be surgically sterile or are using accepted contraceptive methods, from the administration of the first dose of the investigational * the clinical diagnosis of patients must meet the criteria for "diagnosis of idiopathic parkinson's disease" according to the modified ukpds brain bank criteria (see appendix e) * modified hoehn and yahr stage 1 to 2 exclusion criteria: * diagnosis is unclear or a suspicion of other parkinsonian syndromes exists, such as secondary parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndromes or heredodegenerative diseases * patients who have undergone surgery for the treatment of parkinson's disease (eg, pallidotomy, deep brain stimulation, foetal tissue transplantation) or have undergone any other brain surgery * presence of significant dyskinesias, motor fluctuations, swallowing difficulties or loss of postural reflexes patients with a history of non-response (according to both the clinician and the patient) to an adequate course of l-dopa or a da agonist * use of pergolide, selegiline, metoclopramide, strong cyp3a4 inhibitors, cyp3a4 inducers (including st john's wort) and strong cyp1a2 inhibitors and inducers, within 1 month of randomisation;

Keywords: phase iia azd3241 microglia activation safety pharmacodynamics and pharmacokinetics analyses parkinson patients
objective eeg bed side assessment of impaired conscious awareness in epilepsy

Conditions: Epilepsy, Absence

Summary: in this project eeg recordings between healthy participants and those with a diagnosed absence-epilepsy will be compared. the investigators suggest differences in eeg microstate analysis and neuropsychological parameters related to interictal cognitive impairment in these patients. this projects goal is to derive an eeg-based measure of conscious awareness.

this projects goal is to derive an eeg-based measure of conscious awareness to be applied in the care for epilepsy patients. the established terminology of "ictal" versus "interictal" is deceptive because it suggests that during the "interictal" phase epileptic activity is absent and detrimental mechanisms of the disease are only active during seizures. but evidence exists that cognitive impairment extends to states traditionally considered interictal. the development of an objective, ideally ambulatory test assessing cognitive impairment would not only provide a deeper understanding of the pathology but induce a change in clinical practice: if cognitive impairment could be demonstrated "interictally", this fact would help to weigh treatment effects against potential side-effects. in this project the investigators will set out to 1. identify eeg markers in healthy volunteers, which reflect the changes in spatial and temporal dynamics of neuronal activity during states of reduced conscious awareness using sleep as an example of a state of reduced conscious awareness; 2. assess with neuropsychological testing reductions in interictal conscious awareness in patients with epilepsy; 3. test, whether markers established under (1) are valid in individuals with epilepsy and interictally reduced conscious awareness (see (2)).

Eligibility criteria:
inclusion criteria: * age minimum 18 years * diagnosis of (absence) epilepsy // healthy age-matched controls * being of good health (besides epilepsy in the case group) exclusion criteria: * central nervous system disorders (besides epilepsy in the case group) * substance abuse * pregnancy

Keywords: interictal activity impaired consciousness absence epilepsy
a randomized controlled trial of hiv testing and linkage to care at community corrections

Conditions: HIV

Summary: the investigators propose to conduct both a randomized trial of hiv testing in community corrections, and a randomized trial of linkage to hiv care for people with hiv recruited through community corrections (probation and parole).

the first study is a two-group randomized controlled trial in which 6,000 male and female probationers and parolees in baltimore city, maryland and providence, rhode island will be randomly assigned to one of two treatment conditions: 1) on-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office; or 2) off-site referral for rapid hiv testing at a community health center or hiv testing clinic. inclusion criteria will be: 1) adult probationer/parolee; 2) not known to be hiv positive, and 3) resident of greater baltimore or providence throughout the study period. exclusion criteria will be: 1) unable to give informed consent. the second study is a randomized trial, whereby all individuals identified at community corrections with hiv will be offered enrollment in a one-year intervention study to examine the ability to improve linkage into hiv care. participants will be randomized to receive one of two conditions: 1) project bridge for one year, or 2) treatment as usual-referral to standard level of care. moreover, those randomized to tau will be given an opportunity to "crossover" to pb if they have failed to engage in treatment during the first three months. the rationale for choosing the two cities of baltimore, md and providence, ri is due to the historically high rates of heroin addiction that is associated with multiple hiv-related risk behaviors in these two cities and a high likelihood of being on probation and/or parole. furthermore, maryland ranks 10th and rhode island ranks 4th in the nation in the number of probationers per 100,000 adult residents.

Eligibility criteria:
inclusion criteria: 1. probation or parole; 2. resident of baltimore, md or providence, ri; 3) willing to be tested for hiv

Keywords: seek test treat
detection of 2019 novel coronavirus in multiple organ system and its relationship with clinical manifestations

Conditions: Coronavirus

Summary: outbreak of 2019 novel coronavirus infection quickly spread to the world. confirmed patients were isolated and treated in our department. 2019 novel coronavirus was detected in multiple organ system. clinical data was recorded to investigate the its relationship with viral detection.

medical date of suspected patients of 2019 novel coronavirus infection, who came to outpatient department of the third affiliated hospital of sun yat-sen university, were sent to an expert group if they met the inclusion criteria. the expert group discussed and made a decision if the patient would be admission to isolation unit. pharyngeal swabs of the patients were obtained and sent to local center for disease control and prevention (cdc) for detection the 2019 novel coronavirus after patients were admission to isolation unit. diagnosis of 2019 novel coronavirus infection was confirmed if the result was positive or excluded if two consecutive results were negative. patients' demographic data and clinical characteristics were recorded. clinical characteristics including epidemiological history, past history, personal history, symptoms, signs, blood cells count, biochemical test results, chest computed tomography (ct) images. 2019 novel coronavirus rna was detected in pharyngeal swab, anal swab, urine and blood samples by using quantitative real-time polymerase chain reaction (qpcr). comprehensive treatments were given to the patients.

Eligibility criteria:
inclusion criteria: 1. epidemiological history including resident of hubei province, or travel history to hubei province or exposure to suspected patients in the past two weeks. 2. symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest tightness, dyspnea, etc. 3. white blood cells decreased or were normal, or lymphocytes decreased, and chest ct images showed typical findings of viral pneumonia. 4. detection of 2019 novel coronavirus nucleic acid is positive by local center for disease control and prevention (cdc). exclusion criteria: 1. patients can not follow-up; 2. investigator considering inappropriate.

Keywords: 2019 novel coronavirus
a study of isoprinosine in patients with severe aids

Conditions: HIV Infections

Summary: to evaluate the effect of isoprinosine in patients diagnosed as having aids relative to: laboratory (immunologic defects): * comparison of total helper and suppressor t-cell numbers among the groups. * comparison of changes in natural killer cell activity. * comparison of other laboratory findings among the groups. clinical changes: * comparison of the frequency of opportunistic infections among the groups. * comparison of the frequency of the development of aids-related malignancies. * comparison of other clinical manifestations relative to severity and time of onset.


Eligibility criteria:
exclusion criteria co-existing condition: patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded. concurrent medication: excluded: * steroids. * cytotoxic immunosuppressive agents. * radiotherapy. the following are excluded: * critically ill patients. * patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy. * patients who have received any other immunotherapy. * patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer. prior medication: excluded: * any other immunotherapy. patients with severe aids and specified laboratory immunologic defects.

Keywords: infusions, intravenous drug evaluation administration, oral acquired immunodeficiency syndrome aids-related complex zidovudine biological availability
a study to assess recurrence of actinic keratosis in participants treated with methyl aminolevulinate hydrochloride cream or vehicle cream who achieved complete response to treated lesions in earlier study

Conditions: Keratosis, Actinic

Summary: the primary purpose for this study is to assess recurrence of actinic keratosis in participants achieving complete response treated in earlier study.

this is a double-blind, multicenter, long-term follow-up study. the primary purpose of this study is to assess recurrence of actinic keratosis in participants treated with methyl aminolevulinate hydrochloride (mal) 16.8 percent (%) cream (cd06809-41) or vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (dl-pdt), for participants achieving complete response of treated lesions at final visit in study rd.06.spr.112199 (nct04085367).

Eligibility criteria:
inclusion criteria: * participants who have completed earlier study rd.06.spr.112199 (nct04085367) and achieved complete response at last visit * participants fully understand and sign an informed consent form (icf) before any study procedure begins * participants willing and able to perform all study protocol requirements exclusion criteria: * participants developing or experiencing any condition that may not be safe for them or not compliant will be excluded * pertinent not compliant with study conditions or pi instructions during the earlier study - lumexia ph 3
short neck aaa randomized trial - esar and fevar: socrates

Conditions: Aortic Aneurysm, Abdominal

Summary: the aim of this randomized study is to compare the safety and performance of endovascular aneurysm repair with esar using endurant + heli-fx™ endoanchor™ system and fevar using customizable grafts from cook (zenith fenestrated graft) and terumo (fenestrated anaconda graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).


Eligibility criteria:
inclusion criteria: * subject is \>18 years old * subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm * subject is not a candidate for safe, effective and durable standard evar due to challenging anatomical criteria as confirmed by the core lab screening * subject is able and willing to comply with the protocol and to adhere to the follow-up requirements. * subject has provided written informed consent ct angiographic inclusion criteria * subject meets the other anatomical requirements according to the locally applicable endurant ii/iis stent graft system, heli-fx endoanchor system, terumo fenestrated anaconda (available in eu only) and/or cook zenith fenestrated graft instructions for use * proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm * aortic neck diameter from 19 to 31mm * infrarenal neck angulation ≤45° exclusion criteria: * subject is participating in a concurrent study which may confound study results * subject has a life expectancy \<2 year * subject is female of childbearing potential in whom pregnancy cannot be excluded * subject with egfr \<30 ml/min/m2 (kdoqi classification - exclude class iv and above) and or on dialysis * subject with a mi or cva within 3 months prior to index procedure * subject with known connective tissue disease * subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment * subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm * subject requires emergent aneurysm treatment, for example, trauma or rupture * subject has a known hypersensitivity or allergies to study device implant material * subject has an aneurysm that is: * suprarenal, pararenal, or thoracoabdominal * mycotic * inflammatory * pseudoaneurysm * subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential \>50% * pre-op stenosis of the renal arteries \> 50% * subject has active infection or history of covid-19. history of covid-19 is defined as availability of positive covid-19 test with sequelae or hospitalization for treatment of covid-19.
merck iisp stewardship grant for antibiotic best practices

Conditions: Antibiotic Resistant Infection

Summary: the purpose of this study is to pilot the use of best practices alerts to enhance an antimicrobial stewardship program using the electronic medical record, epic.

the purpose of this study is to pilot the use of best practices to enhance an antimicrobial stewardship program using the electronic medical record, epic. screening information technology tools via setnet/safety surveyor(premier) and the electronic anti-infective order form would allow for sufficient medical record review to create best practices alerts for the purpose of appropriate de-escalation of anti-invectives.

Eligibility criteria:
inclusion criteria: * physicians with prescribing privileges at the uwhc exclusion criteria: * none

Keywords: deescalation best practice alert antimicrobial stewardship
reduced target delineation and radiation doses chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: to determine the efficacy and safety of sequential chemoradiotherapy with regimen of docetaxel, cisplatin and fluorouracil and reduced target delineation and radiation doses imrt for patients with locoregionally advanced nasopharyngeal carcinoma

although concurrent chemoradiation is the standard treatment modality for locally advanced nasopharyngeal carcinoma (npc), high incidences of distant metastases and severe treatment related toxicities have become an obstacle to be overcome. besides, a common problem in locally advanced npc is the narrow gap between the tumor and critical normal structures, which makes dose optimization difficult. considering that significant tumor shrinkage may occur during induction chemotherapy, and incidences of distant metastases may be reduced by adjuvant chemotherapy, this study was designed to explore the efficacy and safety of sequential chemoradiotherapy with regimen of docetaxel, cisplatin and fluorouracil and reduced target delineation and radiation doses imrt for patients with locoregionally advanced npc.

Eligibility criteria:
inclusion criteria: 1. histopathologically proven nasopharyngeal carcinoma (who type 2 or 3) 2. stage ⅲ-ⅳb disease (ajcc/uicc 2010) 3. kps more than 70 4. life expectancy of more than 6 months 5. signed written informed consent 6. adequate organ function including the following: absolute neutrophil count (anc) \>= 1.5 \* 109/l platelets count \>= 100 \* 109/l hemoglobin \>= 10 g/dl ast and alt \ = 50 ml/min serum creatine \<= 1 times uln exclusion criteria: 1. evidence of distant metastasis 2. prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region 3. other previous or concomitant cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma 4. pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures 5. presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia

Keywords: nasopharyngeal carcinoma reduced target delineation and radiation doses sequential chemoradiotherapy
roll-over study to allow continued access to ribociclib

Conditions: Metastatic Breast Cancer

Summary: this is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the investigator, would benefit from continued treatment.

the purpose of this study is to evaluate long-term safety and provide continued treatment to participants who are currently receiving ribociclib in combination with other drugs in a parent study, that has fulfilled requirements for its primary objective(s), and in the opinion of the investigator, would benefit from continuing treatment at time of discontinuation from the parent study

Eligibility criteria:
key inclusion criteria: 1. currently participating in a novartis sponsored global study (parent study), receiving treatment with ribociclib in combination with other drugs, and the parent study has fulfilled its primary objective(s) 2. must have been receiving treatment with ribociclib for at least 6 cycles in the parent study 3. currently has evidence of clinical benefit as determined by the investigator key exclusion criteria: 1. permanent discontinuation of ribociclib in the parent study 2. currently has unresolved toxicities for which ribociclib dosing has been interrupted in the parent study 3. local access to commercially available ribociclib and reimbursed other protocol-defined inclusion/exclusion criteria may apply at the end

Keywords: roll-over protocol ribociclib hr-positive her2-negative breast cancer ribociclib in combination with other drugs lee011
transcultural adaptation and validation to spanish of the ospro questionnaires

Conditions: Musculoskeletal Pain

Summary: clinical guidelines for managing musculoskeletal pain recommend first, assessing and identifying any signs of severe physical conditions (i.e."red flags") and then, asessing the psychosocial prognostic factors of poor outcomes (i.e."yellow flags"). the optimal sreening for prediction of referral and outcome (ospro) cohort studies were designed to develop and validate standard assessment tools for review of systems (ospro-ros) and yellow flags (ospro-yf).

the objectives of this study were to translate and cross-cultural adapt ospro-ros and ospro-yf questionnaires to spanish and to investigate their psychometric properties for their use in subjects with musculoskeletal pain.to accomplish the objectives proposed, this study was developed in two phases:phase i: cross-cultural adaptation process.phase ii: psychometric properties evaluation.

Eligibility criteria:
inclusion criteria: ospro-ros: 1. were coming to the emergency department on their first visit. 2. with acute musculoskeletal pain. 3. were able to read and comprehed spanish language. ospro-yf: 1. were seeking outpatient physical therapy treatment. 2. with chronic musculoskeletal pain involving the cervical spine, lumbar spine, shoulder or knee. 3. were able to read and comprehend spanish language. exclusion criteria: 1. widespread chronic pain syndrome (e.g. fibromyalgia or irritable bowel syndrome). 2. neuropathic pain syndrome (e.g. complex regional pain syndrome or diabetic neuropathy). 3. psychiatric history (currently in care of mental health care provider or taking \> 2 precription psychiatric medications) 4. cancer (currently receiving treatment for active cancer) 5. neurological disorder (e.g. stroke, spinal cord injury, or traumatic brain injury).

Keywords: ospro review of systems red flags psychosocial factors yellow flags cross-cultural reliability validity
safety study of pandemic candidate influenza vaccines in the elderly population

Conditions: Influenza; Influenza Vaccines

Summary: influenza pandemics are caused by viruses that possess an hemagglutinin molecule to which most of the population lacks immunity. if such virus is pathogenic to human and demonstrates the ability to transmit from person to person, the result is a global outbreak of disease that affects a high percentage of individuals in a short period of time and is likely to cause substantially increased mortality and morbidity in all countries of the world. recently, purely avian influenza viruses, including the h5n1, h9n2 and h7n7 subtypes, have been directly transmitted to humans, raising concern over the possibility of a new influenza pandemic among the world's immunologically naive populations. in order to face this kind of situation, a pandemic influenza vaccine has to be developed.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol * a male or female aged over 60 years at the time of vaccination. * written informed consent obtained from the subject. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of the study vaccine, or planned use during the study period. * participation in an earlier study with a candidate pandemic h9n2 vaccine. * acute disease at the time of enrolment. * acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * drug and/or alcohol dependency.

Keywords: prophylaxis of pandemic influenza